Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that it plans to report its financial results for its fiscal first
quarter ended December 31, 2015 after the U.S. markets close on February
8, 2016. Enanta management will host a conference call at 4:30 p.m. ET
to discuss these results and provide an update on Enanta’s research and
development pipeline.
Conference Call and Webcast Information
To participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the conference
call will be available starting at approximately 7:30 p.m. Eastern time
on February 8, 2016, through 11:59 p.m. Eastern time on February 12,
2016 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for
international callers. The passcode for both the live call and the
replay is 36743436. A live audio webcast of the call and replay can be
accessed by visiting the “Calendar of Events” section on the “Investors”
page of Enanta’s website at www.enanta.com.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development is currently focused on four disease targets:
Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV). Enanta has
developed novel protease inhibitors and NS5A inhibitors that are members
of the direct-acting-antiviral (DAA) inhibitor classes designed for use
against the hepatitis C virus (HCV). Enanta’s protease inhibitors,
developed through its collaboration with AbbVie, include paritaprevir,
which is contained in AbbVie’s marketed DAA regimens for HCV, and
ABT-493, Enanta’s next-generation protease inhibitor, which AbbVie is
developing in phase 3 studies in combination with ABT-530, AbbVie’s
next-generation NS5A inhibitor. Enanta has also discovered a cyclophilin
inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is
now in a phase 1 clinical development, and EDP-305, an FXR agonist,
which Enanta plans to advance into clinical development for NASH later
in 2016. Please visit www.enanta.com
for more information on our programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005123/en/
Copyright Business Wire 2016